Treatment of Metastatic Triple-Negative Breast Cancer
The Pharma Data
MARCH 25, 2021
SG is a first-in-class therapy targeting Trop-2, a protein frequently expressed in multiple types of epithelial tumors, such as TNBC, where high expression is associated with poor survival and relapse. Canada, Switzerland and Australia, as well as in Singapore through our partner Everest Medicines. Gilead Sciences, Inc.
Let's personalize your content